Foundation Medicine
| Foundation Medicine
|
|
|---|---|
 |
|
| legal form | Incorporated |
| founding | 2010 |
| Seat | Cambridge , MA USA |
| management | Troy Cox, CEO ; Steven Kafka President |
| sales | $ 116.9 million (2016) |
| Branch | pharmacy |
| Website | www.foundationmedicine.com |
Foundation Medicine is an American biopharmaceutical company specializing in genetic testing , founded in 2010 and listed on the American technology exchange NASDAQ under the FMI label. Foundation Medicine is headquartered in Cambridge , MA , USA .
Foundation Medicine assists clinicians in clinical decision-making by producing a report that describes the genomic profile of a patient's tumor as well as the associated approved therapies and relevant clinical trial information.
Targeted Therapy
For a long time, cancer has been categorized and treated based on its anatomical site of origin in the body, e.g. B. lungs, breasts, intestines, skin, etc. In the meantime, oncologists and pathologists are increasingly also considering genetic changes in cancer genes. One also speaks of personalized medicine .
Testing
Foundation Medicine's tests provide biomarker information that enables patients to be reconciled with approved targeted therapies, immunotherapies, and / or clinical trials. They provide physicians and patients with meaningful, actionable insights for making cancer treatment decisions. The company offers a full range of comprehensive genomic profiling assays that can be used to identify the molecular changes in a patient's cancer and match them with relevant targeted therapies, immunotherapies, and clinical trials. Foundation Medicine's molecular information platform aims to improve the daily care of patients by serving the needs of clinicians, academic researchers, and drug developers to advance the science of molecular medicine in cancer.
- FoundationOne was approved by the US FDA in December 2017 . In FoundationOne Cdx is a comprehensive genomic profiling service for solid tumors, potentially meaningful information delivered via the molecular profiling of 324 genes which are known to promote cancer growth. FoundationOne is intended to be used as a comprehensive companion diagnostic for patients with certain types of NSCLC , melanoma , colon cancer , ovarian cancer and / or breast cancer . The aim is to identify those patients who can benefit from treatment with one of 17 targeted therapies after changes in the EGFR, ALK, BRAF, ERBB2, KRAS, NRAS, and BRCA1 / 2 genes have been identified.
- Further tests are FoundationAct , FoundationFocus and FoundationOne HEME.
history
The company was founded in 2010. Roche acquired in April 2015, controlling interest in Foundation Medicine and markets since the service portfolio of Foundation Medicine in countries outside the US, with more than 20 countries on three continents FoundationOne have launched.
See also
Web links
Individual evidence
- ↑ a b A Culture Dedicated to Advancing Cancer Care , Company WebSite, accessed December 6, 2017
- ↑ Contact , Company WebSite, accessed December 6, 2017
- ^ Leadership , Company WebSite, accessed December 6, 2017
- ^ Foundation Medicine Announces 2016 Fourth Quarter and Year-End Results, Recent Highlights and 2017 Outlook , PM FoundationOne, February 22, 2017, accessed December 6, 2017
- ↑ Foundation Medicine, Inc. Real-Time Quotes, NASDAQ WebSite, accessed December 6, 2017
- ↑ a b FDA approves Foundation Medicine's FoundationOne CDx, the first pan-tumor comprehensive genomic profiling assay incorporating a broad range of companion diagnostics PM Roche on December 4, 2017, accessed on December 6, 2017
- ^ FoundationOne , Company WebSite, accessed December 6, 2017
- ^ Our Diagnostic Portfolio , Company WebSite, accessed December 6, 2017